Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (31-40 of 261) with videos related to

Pageof 27
Sort By:
Plos One|January 18, 2024
Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register studyMarcus Westerberg, Sandra Irenaeus, Hans Garmo, et al.
Scandinavian Journal of Urology|April 28, 2021
Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort studyKarl-Johan Lundström, Hans Garmo, Rolf Gedeborg, et al.
BMC Medical Informatics and Decision Making|June 1, 2019
How to measure temporal changes in care pathways for chronic diseases using health care registry dataEugenio Ventimiglia, Mieke Van Hemelrijck, Lars Lindhagen, et al.
European Urology|September 28, 2011
Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Plos One|July 28, 2021
A drug comorbidity index to predict mortality in men with castration resistant prostate cancerGiuseppe Fallara, Rolf Gedeborg, Anna Bill-Axelson, et al.
BMC Medical Informatics and Decision Making|November 20, 2015
How to model temporal changes in comorbidity for cancer patients using prospective cohort dataLars Lindhagen, Mieke Van Hemelrijck, David Robinson, et al.
Journal of Surgical Oncology|June 19, 2021
Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide studyFrederik B Thomsen, Hans Garmo, Klaus Brasso, et al.
Scandinavian Journal of Urology|April 29, 2024
Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancerFrederik F Thomsen, Hans Garmo, Lars Egevad, et al.
Clinical Epidemiology|December 3, 2025
Discriminative Ability of the Charlson Comorbidity Index for Long-Term Mortality in a General Population: Nationwide, Population-Based Study of 10 Million Adults in SwedenMarcus Westerberg, Hans Garmo, Jonas F Ludvigsson, et al.
The Journal of Urology|January 18, 2011
Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe SwedenAnders Berglund, Hans Garmo, Carol Tishelman, et al.
Pageof 27

Showing results (31-40 of 261) with videos related to

Sort By:
Pageof 27
Plos One|January 18, 2024
Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register studyMarcus Westerberg, Sandra Irenaeus, Hans Garmo, et al.
Scandinavian Journal of Urology|April 28, 2021
Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort studyKarl-Johan Lundström, Hans Garmo, Rolf Gedeborg, et al.
BMC Medical Informatics and Decision Making|June 1, 2019
How to measure temporal changes in care pathways for chronic diseases using health care registry dataEugenio Ventimiglia, Mieke Van Hemelrijck, Lars Lindhagen, et al.
European Urology|September 28, 2011
Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Plos One|July 28, 2021
A drug comorbidity index to predict mortality in men with castration resistant prostate cancerGiuseppe Fallara, Rolf Gedeborg, Anna Bill-Axelson, et al.
BMC Medical Informatics and Decision Making|November 20, 2015
How to model temporal changes in comorbidity for cancer patients using prospective cohort dataLars Lindhagen, Mieke Van Hemelrijck, David Robinson, et al.
Journal of Surgical Oncology|June 19, 2021
Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide studyFrederik B Thomsen, Hans Garmo, Klaus Brasso, et al.
Scandinavian Journal of Urology|April 29, 2024
Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancerFrederik F Thomsen, Hans Garmo, Lars Egevad, et al.
Clinical Epidemiology|December 3, 2025
Discriminative Ability of the Charlson Comorbidity Index for Long-Term Mortality in a General Population: Nationwide, Population-Based Study of 10 Million Adults in SwedenMarcus Westerberg, Hans Garmo, Jonas F Ludvigsson, et al.
The Journal of Urology|January 18, 2011
Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe SwedenAnders Berglund, Hans Garmo, Carol Tishelman, et al.
Pageof 27